You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 8, 2025

Quinethazone - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for quinethazone and what is the scope of freedom to operate?

Quinethazone is the generic ingredient in two branded drugs marketed by Lederle and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

Summary for quinethazone
US Patents:0
Tradenames:2
Applicants:1
NDAs:2
Raw Ingredient (Bulk) Api Vendors: 40
Patent Applications: 4,025
DailyMed Link:quinethazone at DailyMed
Anatomical Therapeutic Chemical (ATC) Classes for quinethazone

US Patents and Regulatory Information for quinethazone

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lederle HYDROMOX R quinethazone; reserpine TABLET;ORAL 013927-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Lederle HYDROMOX quinethazone TABLET;ORAL 013264-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Market Dynamics and Financial Trajectory for Quinethazone

Introduction

Quinethazone, a thiazide diuretic marketed as Hydromox, is used to treat hypertension by inhibiting sodium and chloride reabsorption in the kidneys. To understand the market dynamics and financial trajectory of quinethazone, it is essential to delve into the broader context of the antihypertensive drug market, the role of thiazide diuretics, and specific factors influencing quinethazone's market position.

The Antihypertensive Drug Market

The market for antihypertensive drugs is vast and diverse, with various classes of drugs including thiazide diuretics, beta-blockers, calcium channel blockers (CCBs), angiotensin-converting enzyme (ACE) inhibitors, and angiotensin II receptor blockers (ARBs)[3].

Role of Thiazide Diuretics

Thiazide diuretics, such as quinethazone, have been a cornerstone in the treatment of hypertension for decades. They are known for their effectiveness in reducing blood pressure and their cost-effectiveness compared to other antihypertensive drug classes. Studies have consistently shown that thiazide diuretics are among the most cost-effective options for initial hypertension treatment[3].

Market Share and Utilization

Despite their cost-effectiveness, the market share of thiazide diuretics has seen fluctuations. In Canada, for example, the proportion of prescriptions for thiazide diuretics relative to other antihypertensive classes remained relatively low, ranging from 8% to 22% between 2000 and 2006. However, thiazide diuretics are still widely prescribed due to their efficacy and lower cost[3].

Financial Implications

The financial implications of using thiazide diuretics like quinethazone are significant. Economic evaluations have shown that starting treatment with thiazide diuretics can reduce the yearly increase in expenditure on antihypertensive medications. For instance, a Markov model used to estimate long-term costs and quality-adjusted life-years (QALYs) found that thiazide diuretics are the least costly therapeutic option and offer a high level of effectiveness, making them a financially attractive choice[3].

Competitive Landscape

The competitive landscape for antihypertensive drugs is highly competitive, with multiple classes of drugs and numerous brands within each class. In the market for oral diuretics, for example, the concentration of sales among a few leading firms is high, but non-leading firms often spend a higher percentage of their sales on promotion to compete[1].

Promotion and Product Differentiation

Promotion plays a crucial role in the pharmaceutical industry, especially in markets with differentiated products. The study by the Federal Trade Commission found that non-leading firms in the antianginal and oral diuretic markets spent more on promotion relative to their sales compared to leading firms. This trend could influence the market dynamics for quinethazone, as it may require significant promotional efforts to maintain or increase its market share[1].

Regulatory and Patent Considerations

Quinethazone, as a thiazide diuretic, operates in a market where patent protection is a significant factor. The introduction of new drugs and the expiration of patents can significantly impact the market dynamics. For example, the introduction of thiazide chemicals like quinethazone marked a turning point in diuretic and antihypertensive therapy, replacing older drugs. However, as patents expire, generic versions of these drugs can enter the market, potentially affecting the sales of branded products like quinethazone[1].

Clinical Efficacy and Side Effects

The clinical efficacy of quinethazone is well-documented, but it also comes with potential side effects such as dizziness, dry mouth, nausea, and hypokalemia. These side effects can influence patient compliance and physician prescribing habits, which in turn can affect the drug's market performance[4].

Economic Evaluation

Economic evaluations are critical in assessing the cost-effectiveness of antihypertensive treatments. A study evaluating the clinical effects and economic implications of thiazide diuretics found that they are the most cost-effective therapy for the initial treatment of hypertension. This cost-effectiveness is a key factor in the financial trajectory of quinethazone, as it makes the drug an attractive option for both patients and healthcare systems[3].

Health Services Impact

The impact of thiazide diuretics on health services is significant. If prescribing trends favor thiazide diuretics, the overall expenditure on antihypertensive medications can be reduced. This is particularly important in managing chronic conditions like hypertension, where long-term treatment is often necessary[3].

Ethical, Equity, and Psychosocial Issues

The use of thiazide diuretics raises ethical and equity considerations, particularly in the allocation of healthcare resources. Given their cost-effectiveness, there is a need to ensure equitable access to these drugs. Patients should be informed about the benefits and risks of diuretic therapy, and lifestyle modifications should be encouraged to complement pharmacological treatment[3].

Key Takeaways

  • Cost-Effectiveness: Thiazide diuretics like quinethazone are among the most cost-effective options for treating hypertension.
  • Market Share: Despite their efficacy, thiazide diuretics have a relatively low market share compared to other antihypertensive classes.
  • Promotion: Non-leading firms in the antihypertensive market often spend more on promotion to compete.
  • Regulatory Factors: Patent protection and the introduction of new drugs can significantly impact the market dynamics.
  • Clinical Efficacy: Quinethazone is effective but comes with potential side effects that can influence market performance.
  • Economic Evaluation: Thiazide diuretics are economically favorable, reducing long-term healthcare expenditures.

FAQs

What is quinethazone used for?

Quinethazone is a thiazide diuretic used to treat hypertension by inhibiting sodium and chloride reabsorption in the kidneys.

How does quinethazone compare to other antihypertensive drugs in terms of cost?

Quinethazone and other thiazide diuretics are generally more cost-effective than other classes of antihypertensive drugs.

What are the potential side effects of quinethazone?

Potential side effects include dizziness, dry mouth, nausea, and hypokalemia.

How does the market share of thiazide diuretics like quinethazone compare to other antihypertensive classes?

The market share of thiazide diuretics is relatively low, ranging from 8% to 22% in some regions, despite their cost-effectiveness.

What is the impact of thiazide diuretics on healthcare expenditure?

Starting treatment with thiazide diuretics can reduce the yearly increase in expenditure on antihypertensive medications.

Sources

  1. Federal Trade Commission: Sales, Promotion, and Product Differentiation in Two Prescription Drug Markets[1].
  2. MalaCards: Hypertension, Essential[2].
  3. Canadian Agency for Drugs and Technologies in Health: Thiazide Diuretics as First-Line Treatment for Hypertension[3].
  4. DrugBank: Quinethazone[4].

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.